PALIZADE TrialPhase 2bLupus Nephritis
PORTOLA TrialPhase 2aAutoimmune Hepatitis
Presidio TrialPhase 2Active Polymyositis or Dermatomyositis
KZR-261 TrialPhase 1Advanced Solid Malignancies
Expanded Access Policy /
Compassionate Use Policy
Kezar Life Sciences is committed to developing safe and effective therapies for serious diseases that impact patients and their families. To achieve this, we conduct clinical trials to assess the risks and benefits of our investigational therapies. The safety and efficacy data generated from clinical trials can be used to obtain regulatory approvals, leading to the widest availability for patients.
Expanded access, also known as compassionate use, named-patient use or single-patient access, refers to the use of an investigational therapy, which has not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory agencies, to treat patients who have serious or life-threatening diseases outside of a clinical trial. Currently, we do not have an expanded access program in place.
At this time, participation in one of our clinical trials is the only way to access our investigational therapies. We believe that clinical trials provide the safest opportunity for patients to access an investigational therapy before it is approved by a regulatory agency. For information regarding our clinical trials, please refer to www.clinicaltrials.gov.
If you have questions about our clinical trials or our expanded access policy, please speak with your physician or contact us at firstname.lastname@example.org.
In accordance with the 21st Century Cures Act, Kezar may change this policy at any time as more clinical information becomes available on our investigational therapies. The website and policy will be updated to reflect any changes as they are implemented.